CCR7 alterations associated with inferior outcome of adult T‐cell leukemia/lymphoma under mogamulizumab treatment

Adult T‐cell leukemia/lymphoma (ATL) patients have a very poor prognosis. The humanized anti‐CCR4 therapeutic monoclonal antibody, mogamulizumab, is a key agent for ATL treatment. Our previous integrated molecular analysis demonstrated that among all the driver genes in ATL, CCR7 gene alterations we...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakamoto, Yuma, Ishida, Takashi, Masaki, Ayako, Murase, Takayuki, Ohtsuka, Eiichi, Takeshita, Morishige, Muto, Reiji, Iwasaki, Hiromi, Ito, Asahi, Kusumoto, Shigeru, Nakano, Nobuaki, Tokunaga, Masahito, Yonekura, Kentaro, Tashiro, Yukie, Iida, Shinsuke, Utsunomiya, Atae, Ueda, Ryuzo, Inagaki, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087024/
https://www.ncbi.nlm.nih.gov/pubmed/36043457
http://dx.doi.org/10.1002/hon.3072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087024/
https://www.ncbi.nlm.nih.gov/pubmed/36043457
http://dx.doi.org/10.1002/hon.3072

Ejemplares similares